Immunotherapy for Chronic Hepatitis B Virus Infection
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal. Although current direct antiviral therapies are very efficient in controlling viral replication and limiting the progression to cirrhosis, these treatments require lifelong administration due to the frequent viral rebound upon treatment cessation, and immune modulation with interferon is only effective in a subgroup of patients. Specific immunotherapies can offer the possibility of eliminating or at least stably maintaining low levels of HBV replication under the control of a functional host antiviral response. Here, we review the development of immune cell therapy for HBV, highlighting the potential antiviral efficiency and potential toxicities in different groups of chronically infected HBV patients. We also discuss the chronic hepatitis B patient populations that best benefit from therapeutic immune interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection
Pallett, L. J., Davies, J., Colbeck, E. J., Robertson, F., Hansi, N., Easom, N. J. W., Burton, A. R., Stegmann, K. A., Schurich, A., Swadling, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162115 · Cited by 347
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion
Peppa, D., Gill, U. S., Reynolds, G., Easom, N. J. W., Pallett, L. J., Schurich, A., Micco, L., Nebbia, G., Singh, H. D., Adams, D. H., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121172 · Cited by 342 · cited 1×
“However, at present it is not clear whether NK cells preferentially target HBV-infected hepatocytes or have a regulatory capacity on HBV-specific T cells.(22) Similarly, even though anti-HBs antibodies have protective capacity and a defective humoral response has been implicated in HBV chronicity, the quantity and fun…”
BackgroundFunctional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072076 · Cited by 256
Self-citationGill, U. S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M. J. W., Barr, D. A., Kallis, Y. N., Marley, R. T. C., Kooner, P., Foster, G. R., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu471 · Cited by 93
Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease
Tan-Garcia, A., Wai, L.-E., Zheng, D., Ceccarello, E., Jo, J., Banu, N., Khakpoor, A., Chia, A., Tham, C. Y. L., Tan, A. T., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.023 · Cited by 68 · cited 2×
“We have recently demonstrated an enrichment of inflammatory monocytes in the intrahepatic environment of patients with advanced liver pathologies.(89) These myeloid cells do not carry the classical anti-inflammatory features of resident intrahepatic monocytes (Kupffer cells), but are constantly producing inflammatory…”
BackgroundSelf-citation
Cited by
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Self-citationYoo, S., Lee, D., Shim, J. H., Kim, K. M., Lim, Y.-S., Lee, H. C., Yoo, C., Ryoo, B.-Y., & Choi, J. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.019 · Cited by 73
Metadata
- Authors
- Bertoletti, A., & Bert, N. L.
- Venue
- Gut and Liver
- Published
- 2018-09-15
- Volume
- 12
- Issue
- 5
- Pages
- 497-507
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W3098422096
- Cited by
- 110
- References
- 8
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy for Chronic Hepatitis B Virus Infection. https://app.cochat.ai/papers/10.5009/gnl17233
- The paper
- Bertoletti, A., & Bert, N. L. (2018). Immunotherapy for Chronic Hepatitis B Virus Infection. Gut and Liver. https://doi.org/10.5009/gnl17233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.